| |
Audit
|
Nominating and Governance
|
Compensation
|
Strategic
|
John T. Henderson M.D.
|
|
|
|
|
 Chairman of the Board
John T. Henderson, M.D. was elected as Chairman of the Board in April 2005. He previously served as a Director of the Company effective May 2004. Dr. Henderson was with Pfizer for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Europe, U.S. and International Pharmaceuticals group. Dr. Henderson earned his bachelor's and medical degree from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.).
|
|
Peter D. Meldrum
|
|
|
|
|
 President and CEO
Peter D. Meldrum has been a Director of the Company since its inception in May 1991 and has been President and Chief Executive Officer of the Company since November 1991. Prior to joining the Company he was President and Chief Executive Officer of Founders Fund, Inc., a venture capital group. He received a Doctor of Engineering degree (honorary) from the University of Utah in 2009, a Doctor of Science degree (honorary) from Westminster College in 2004, an M.B.A. degree from the University of Utah in 1974, and a B.S. degree in Chemical Engineering from the University of Utah in 1970.
|
Holdings: 180,921 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Feb 1, 2012 |
Automatic Sell |
15,200 |
24.38 |
| Feb 1, 2012 |
Option Execute |
15,200 |
3.80 |
| Jan 31, 2012 |
Automatic Sell |
15,000 |
23.51 |
| Jan 31, 2012 |
Option Execute |
15,000 |
3.80 |
| Jan 26, 2012 |
Automatic Sell |
12,205 |
23.05 |
| Jan 26, 2012 |
Option Execute |
12,205 |
3.80 |
| Jan 25, 2012 |
Automatic Sell |
2,795 |
23.00 |
| Jan 25, 2012 |
Option Execute |
2,795 |
3.80 |
| Aug 25, 2011 |
Option Execute |
5,808 |
12.17 |
| Jun 15, 2011 |
Sell |
20,000 |
23.99 |
| Jun 15, 2011 |
Option Execute |
20,000 |
20.24 |
| May 25, 2011 |
Sell |
20,000 |
25.00 |
| May 25, 2011 |
Option Execute |
20,000 |
20.24 |
| May 18, 2011 |
Sell |
20,000 |
24.67 |
| May 18, 2011 |
Option Execute |
20,000 |
20.24 |
| Dec 15, 2010 |
Disposition (Non Open Market) |
37,500 |
n/a |
| May 7, 2010 |
Option Execute |
8,196 |
8.63 |
| Mar 8, 2010 |
Sell |
30,754 |
22.30 |
| Mar 8, 2010 |
Option Execute |
30,754 |
8.86 |
| Mar 5, 2010 |
Sell |
25,037 |
22.95 |
| Mar 5, 2010 |
Option Execute |
25,037 |
8.86 |
| Mar 4, 2010 |
Sell |
21,285 |
23.00 |
| Mar 4, 2010 |
Option Execute |
21,285 |
8.86 |
| Dec 11, 2009 |
Option Execute |
9,726 |
7.27 |
| Aug 28, 2009 |
Disposition (Non Open Market) |
28,713 |
n/a |
| Feb 23, 2009 |
Option Execute |
4,863 |
20.56 |
| Feb 5, 2009 |
Sell |
15,000 |
83.14 |
| Feb 5, 2009 |
Option Execute |
15,000 |
25.06 |
| Feb 3, 2009 |
Automatic Sell |
10,000 |
79.58 - 84.57 |
| Nov 4, 2008 |
Automatic Sell |
10,000 |
69.09 - 71.25 |
| Nov 4, 2008 |
Disposition (Non Open Market) |
13,000 |
n/a |
| Sep 2, 2008 |
Option Execute |
9,727 |
20.56 - 35.76 |
| Aug 29, 2008 |
Sell |
15,998 |
68.07 |
| Aug 29, 2008 |
Option Execute |
15,998 |
4.78 |
| Mar 10, 2008 |
Option Execute |
2,462 |
25.06 |
| Dec 7, 2007 |
Disposition (Non Open Market) |
8,250 |
n/a |
| Oct 15, 2007 |
Automatic Sell |
20,000 |
55.02 - 55.59 |
| Sep 14, 2007 |
Sell |
11,262 |
47.00 - 47.15 |
| Sep 14, 2007 |
Option Execute |
11,262 |
9.31 |
| Sep 12, 2007 |
Sell |
10,000 |
47.14 - 47.30 |
| Sep 12, 2007 |
Option Execute |
10,000 |
9.31 |
| May 4, 2007 |
Sell |
20,000 |
39.38 |
| May 4, 2007 |
Disposition (Non Open Market) |
8,675 |
n/a |
| May 2, 2007 |
Automatic Sell |
9,400 |
38.00 |
| May 1, 2007 |
Automatic Sell |
600 |
38.00 |
| Apr 27, 2007 |
Disposition (Non Open Market) |
555 |
n/a |
| Jan 12, 2007 |
Automatic Sell |
10,000 |
35.00 |
| Jan 10, 2007 |
Automatic Sell |
10,000 |
33.00 |
| Dec 13, 2006 |
Automatic Sell |
20,000 |
30.89 - 30.91 |
| Dec 11, 2006 |
Disposition (Non Open Market) |
5,800 |
n/a |
|
|
Lawrence C. Best
|
|
|
|
|
 Director
Chairman and Founder of OXO Capital LLC
Lawrence C. Best, a Director of the Company since September 2009, joined Boston Scientific Corporation in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. He served a two-year fellowship at the SEC from 1979 to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C. He currently serves on the Board of Directors of Haemonetics Corp. and is a founding director of the President's Council at Massachusetts General Hospital. Mr. Best received a B.B.A. degree from Kent State University.
|
|
Heiner Dreismann, Ph.D.
|
|
|
|
|
 Director
Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.
|
|
Walter Gilbert Ph.D.
|
|
|
|
|
 Director, Vice Chairman of the Board
Managing Director, BioVentures Investors
Walter Gilbert, Ph.D., Vice Chairman of the Board of Directors, joined the Company as a founding scientist in March 1992. Dr. Gilbert won the Nobel Prize in Chemistry in 1980 for his contributions to the development of DNA sequencing technology. He was a founder of Biogen, Inc. and its Chairman of the Board and Chief Executive Officer from 1981 to 1985, as well as the Carl M. Loeb University Professor at Harvard University. He is presently a Managing Director of BioVentures Investors.
|
Holdings: 0 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Sep 5, 2008 |
Sell |
10,000 |
63.31 |
| Sep 5, 2008 |
Option Execute |
10,000 |
21.49 - 29.98 |
| Nov 5, 2007 |
Sell |
29,962 |
52.61 - 53.15 |
| Nov 5, 2007 |
Option Execute |
29,962 |
17.86 - 21.49 |
| Nov 5, 2007 |
Sell |
5,038 |
52.76 - 53.05 |
| Nov 5, 2007 |
Option Execute |
5,038 |
17.86 |
| May 9, 2007 |
Sell |
30,000 |
38.05 |
| May 9, 2007 |
Option Execute |
30,000 |
10.19 - 11.22 |
| Nov 10, 2006 |
Sell |
9,498 |
26.92 |
| Nov 10, 2006 |
Sell |
16,799 |
26.94 |
| Nov 9, 2006 |
Sell |
3,472 |
27.14 |
| Nov 9, 2006 |
Sell |
6,171 |
27.14 |
|
|
Dennis Langer M.D, J.D.
|
|
|
|
|
 Director
Managing Partner, Phoenix IP Ventures
Dennis Langer, M.D., J.D. is a Director of the Company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.
|
Holdings: 0 shares
View Transactions
|
| Date |
Type |
Shares Traded |
Price Range |
| Feb 5, 2009 |
Sell |
15,000 |
82.72 |
| Feb 5, 2009 |
Option Execute |
15,000 |
21.49 - 29.98 |
| Sep 5, 2008 |
Sell |
4,280 |
63.50 |
| Sep 5, 2008 |
Option Execute |
4,280 |
21.49 |
| Sep 4, 2008 |
Sell |
5,720 |
65.73 |
| Sep 4, 2008 |
Option Execute |
5,720 |
21.49 |
| Dec 20, 2007 |
Sell |
20,000 |
47.00 - 48.09 |
| Dec 20, 2007 |
Option Execute |
20,000 |
17.23 - 19.50 |
| Dec 19, 2007 |
Sell |
10,000 |
47.50 - 47.53 |
| Dec 19, 2007 |
Option Execute |
10,000 |
17.23 |
|
|
S. Louise Phanstiel
|
|
|
|
|
 Director
S. Louise Phanstiel joined the Company in September 2009. Ms. Phanstiel held several important positions at WellPoint, Inc. from 1996 to 2007, including President, Specialty Products (2003 to 2007), Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman (2000 to 2003), and Senior Vice President, Chief Accounting Officer, Controller, and Chief Financial Officer for all WellPoint, Inc. subsidiaries, including Blue Cross of California (1996 to 2000). Previously, Ms. Phanstiel was a partner at the international services firm of Coopers and Lybrand where she served clients in life and property/casualty insurance, high technology, and higher education. Ms. Phanstiel formerly served on the Board of Directors of Inveresk Research Group, Inc. and Charles River Laboratories, Inc. Ms. Phanstiel received a B.A. degree in Accounting from Golden Gate University and is a Certified Public Accountant.
|
0.18
